These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33831049)

  • 1. The impact and cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the paediatric immunisation programme in Iceland-A population-based time series analysis.
    Eythorsson E; Ásgeirsdóttir TL; Erlendsdóttir H; Hrafnkelsson B; Kristinsson KG; Haraldsson Á
    PLoS One; 2021; 16(4):e0249497. PubMed ID: 33831049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the 10-valent pneumococcal conjugate vaccine on hospital admissions in children under three years of age in Iceland.
    Sigurdsson S; Eythorsson E; Erlendsdóttir H; Hrafnkelsson B; Kristinsson KG; Haraldsson Á
    Vaccine; 2020 Mar; 38(12):2707-2714. PubMed ID: 32063434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
    Zhang XH; Leeuwenkamp O; Oh KB; Lee YE; Kim CM
    Hum Vaccin Immunother; 2018 Jan; 14(1):85-94. PubMed ID: 29115905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated Annual Health and Cost Impact of PHiD-CV Immunization Program in Brazil.
    Gomez JA; Lopes de Abreu AJ; Caceres DC; Nieto J; Ortega-Barria E
    Pediatr Infect Dis J; 2019 Oct; 38(10):e260-e265. PubMed ID: 31568144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.
    Lagoubi Y; Sfar MT; Gomez JA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079305. PubMed ID: 35703731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age.
    Karppinen S; Toivonen L; Schuez-Havupalo L; Teros-Jaakkola T; Waris M; Auranen K; Palmu AA; Peltola V
    Vaccine; 2019 May; 37(22):2935-2941. PubMed ID: 31027929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
    de Sévaux JL; Venekamp RP; Lutje V; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD001480. PubMed ID: 33231293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct and Indirect Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine Against Carriage in a Cluster Randomized Trial.
    Palmu AA; Toropainen M; Kaijalainen T; Siira L; Lahdenkari M; Nieminen H; Syrjänen RK; Kilpi TM; Jokinen J
    Pediatr Infect Dis J; 2017 Dec; 36(12):1193-1200. PubMed ID: 28737627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in All-Cause Acute Otitis Media in Children <3 Years of Age in Primary Care Following Vaccination With 10-Valent Pneumococcal Haemophilus influenzae Protein-D Conjugate Vaccine: A Whole-Population Study.
    Sigurdsson S; Eythorsson E; Hrafnkelsson B; Erlendsdóttir H; Kristinsson KG; Haraldsson Á
    Clin Infect Dis; 2018 Sep; 67(8):1213-1219. PubMed ID: 29617959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
    Fortanier AC; Venekamp RP; Boonacker CW; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
    Cochrane Database Syst Rev; 2019 May; 5(5):CD001480. PubMed ID: 31135969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
    Palmu AA; Jokinen J; Borys D; Nieminen H; Ruokokoski E; Siira L; Puumalainen T; Lommel P; Hezareh M; Moreira M; Schuerman L; Kilpi TM
    Lancet; 2013 Jan; 381(9862):214-22. PubMed ID: 23158882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
    De Wals P; Black S; Borrow R; Pearce D
    Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand.
    Varghese L; Talbot L; Govender A; Zhang XH; Mungall BA
    Appl Health Econ Health Policy; 2018 Jun; 16(3):331-345. PubMed ID: 29633160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the 10-valent pneumococcal conjugate vaccine on antimicrobial prescriptions in young children: a whole population study.
    Eythorsson E; Sigurdsson S; Hrafnkelsson B; Erlendsdóttir H; Haraldsson Á; Kristinsson KG
    BMC Infect Dis; 2018 Oct; 18(1):505. PubMed ID: 30286726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
    Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
    Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
    Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
    BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.
    Boonacker CW; Broos PH; Sanders EA; Schilder AG; Rovers MM
    Pharmacoeconomics; 2011 Mar; 29(3):199-211. PubMed ID: 21250759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine in a cluster-randomised trial.
    Rinta-Kokko H; Palmu AA; Ruokokoski E; Nieminen H; Moreira M; Schuerman L; Borys D; Jokinen J
    PLoS One; 2022; 17(1):e0261750. PubMed ID: 34986178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.